8 › 8.2
8.2 Management
Pages 54–58 · open in PDF
Recommendations in this section
- Class IIaLevel CDown-titration or discontinuation of beta-blockers or ivabradine should be considered in selected patients with advanced HFrEF and evidence of organ hypoperfusion, despite initial treatment, to increase cardiac output and improve symptoms.
- Class IIaLevel CContinuous inotropes should be considered in patients with advanced HFrEF, low cardiac output, and evidence of hypoperfusion or end-organ dysfunction, as BTD, BTT or as bridge to durable MCS, to increase cardiac output and improve symptoms.
- Class IIaLevel CKidney replacement therapy should be considered in patients with refractory volume overload and end-stage kidney failure to improve symptoms.
- Class IIbLevel CUltrafiltration may be considered in patients with refractory volume overload unresponsive to escalation of diuretic therapy to reduce the risk of rehospitalization.
- Class ILevel CDurable MCS (LVAD) is recommended in selected patients with advanced HFrEF, despite FMT and GDIT, as BTT, BTC, BTR, or as destination therapy to improve symptoms and reduce the risk of death.
- Class IIaLevel CHistopathological examination of explanted heart tissue from LVAD or heart transplantation surgery should be considered in patients with non-ischaemic HF to identify an aetiological diagnosis that may be treatable or facilitate family screening.
- Class ILevel CHeart transplantation is recommended in selected patients with advanced HF refractory to FMT and GDIT, and without contraindications, to improve QoL and survival.
Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.
Page 54 · PDF
patients with advanced HF, as part of the evaluation for heart transplantation and durable MCS.580–582
8.2. Management The indication and timing of advanced HF treatments are guided by patient goals, comorbidities, and clinical status. Pharmacological therapy and temporary MCS may be indicated until implantation of durable MCS or heart transplantation becomes available.543 The SCAI classification may be useful in identifying patients for temporary MCS as a possible bridge to advanced therapies (Table 13). The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profiles592 describe clinical parameters and characteristics consistent with a need for advanced therapies (Figures 17 and 18).
8.2.1. Pharmacological therapy and kidney replacement therapy Every effort should be made to reach target doses of FMT in all patients with HF. However, patients with advanced HF are under-represented in RCTs. Most patients with advanced HF reach a stage where dose reduction or cessation of neurohormonal therapy is necessary due to progressive intolerance. Although evidence is lacking, it is reasonable to perform individualized changes in FMT, and AMT if needed, on a patienttailored basis. For example, in a patient with hypotension and high arrhythmic burden, the ACE-I dose can be reduced so that treatment with beta-blockers can be prioritized. However, in a patient with hypoperfusion and persistently low stroke volume despite therapy, reduction or cessation of beta-blockers may be the first step to maintaining cardiac output. In these cases, amiodarone may be better tolerated than beta-blockers when arrhythmias occur. Most importantly, any of these downtitrations should prompt contact with, or referral to, an advanced HF centre if there are no absolute contraindications for MCS or heart transplantation. AMT implementation should not delay early referral to advanced HF therapies. In patients with signs of hypoperfusion, inotropes may improve haemodynamic parameters, augmenting cardiac output and aiding peripheral perfusion. They may also reduce congestion when the response to diuretic therapy is insufficient. Inotropic therapy is often used to assess reversibility of end-organ dysfunction in the screening phase for durable MCS or heart transplantation, or to maintain cardiac output until such therapies become available (see Supplementary data online, Table S18). Inotropes can be used as palliative therapy for the relief of symptoms in patients without other treatment options (see Supplementary data online, Figure S2).594 However, because inotropic therapy may exacerbate or induce myocardial ischaemia and/or tachyarrhythmias, it should
Recommendation Table 12 — Recommendations for medical management of advanced heart failure (see Evidence Tables 72 and 73) Recommendations
Down-titration or discontinuation of beta-blockers or ivabradine should be considered in selected patients with advanced HFrEF and evidence of organ hypoperfusion, despite initial treatment, to increase cardiac output and improve symptoms. Continuous inotropes should be considered in patients with advanced HFrEF, low cardiac output, and evidence of hypoperfusion or end-organ dysfunction, as BTD, BTT or as bridge to durable MCS, to increase cardiac output and improve symptoms.598,599 Kidney replacement therapy should be considered in patients with refractory volume overload and end-stage kidney failure to 600
Ultrafiltration may be considered in patients with refractory volume overload unresponsive to escalation of diuretic therapy to reduce the 601
risk of rehospitalization.
BTD, bridge to decision; BTT, bridge to transplantation; HFrEF, heart failure with reduced ejection fraction; MCS, mechanical circulatory support. a Class of recommendation. b Level of evidence.
8.2.2. Mechanical circulatory support Mechanical circulatory support can improve survival and symptoms of patients with advanced HF. The use of MCS should be considered for the different scenarios listed in Supplementary data online, Table S19. Indications for temporary and durable MCS should be based on the SCAI classification (Table 13, Section 7) and INTERMACS profiles (Figures 17 and 18).
8.2.2.1. Temporary mechanical circulatory support Temporary MCS devices are indicated in selected patients to reverse critical end-organ hypoperfusion and hypoxia in the setting of CS (see Section 7). The aim is to support cerebral and end-organ perfusion, reverse acidosis and multiorgan failure,
HF, heart failure; LVAD, left ventricular assist device; MCS, mechanical circulatory support. a Class of recommendation. b Level of evidence. c A centre performing LVAD implantation and/or heart transplantation. d Eligibility criteria are reported in Tables 16 and 17. e This recommendation is considered by the Task Force to have level of evidence A due to clear clinical effectiveness.
only be used in the lowest required dose and for as short a period as possible.595,596 Kidney dysfunction and loop diuretic resistance often characterize the clinical course of patients with advanced HF. Doubling the loop diuretic dose or concomitant administration of non-loop diuretics is indicated.265 However, in patients who fail to respond to diuretic-based strategies, kidney replacement therapies should be considered. Ultrafiltration and peritoneal dialysis are the most common approaches. It may be considered in those with diuretic resistance to treat volume overload, even if data about its effects on clinical outcomes are inconclusive.527,597
Right heart catheterization is recommended in
Page 55 · PDF
venous; MCS, mechanical circulatory support; NYHA, New York Heart Association. The INTERMACS classification supports risk stratification and guides the timing of durable MCS or heart transplantation in patients with advanced HF.593 Supplementary data online, Table S18 provides a definition for inotrope dependence.
and provide support until the patient’s trajectory clarifies, whether towards myocardial recovery, transition to durable MCS or heart transplantation, or a palliative pathway. The care of patients on temporary MCS is complex and requires specialized expertise, including predefined strategies for withdrawal of support when there is no meaningful neurological and cardiac recovery. Temporary MCS should be considered in patients with INTERMACS profiles 1 or 2 as a bridge to decision, bridge to recovery, or bridge to either durable MCS or urgent heart transplantation (Figure 18).
8.2.2.2. Durable mechanical circulatory support Durable MCS is indicated to prolong life and improve QoL in selected patients when FMT, and GDIT are insufficient or when temporary MCS has not led to cardiac recovery or clinical improvement (Table 16).602,603 Left ventricular assist device is by far the most common and reliable type of durable MCS; however, in cases with biventricular failure or special anatomical situations, a total artificial heart or implantable biventricular assist device is occasionally used.582 Management of patients who are possible candidates for LVAD or heart transplantation is outlined in Figure 18.
Figure 17 INTERMACS classification. ADLs, activities of daily living; CPET, cardiopulmonary exercise testing; HF, heart failure; i.v., intra-
Page 56 · PDF
BTR, bridge to recovery; BTT, bridge to transplantation; CA, cardiac amyloidosis; CMP, cardiomyopathy; DT, destination therapy; ESC, European Society of Cardiology; HCM, hypertrophic cardiomyopathy; HF, heart failure; HFA, Heart Failure Association; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LVAD, left ventricular assist device; MCS, mechanical circulatory support. The figure depicts a guidance for advanced HF treatment based on clinical profile. Colour code for classes of recommendation: green for Class of recommendation I and yellow for Class of recommendation IIa. This algorithm can be applied to all patients with advanced HF defined according to the ESC/HFA criteria, with exception of arrhythmic storm, and refractory angina. HCM, CA, other restrictive CMP, ARVC, and adult congenital heart disease are other exceptions. aTo be discussed with the Shock Team. bRecurrent hospitalization, progressive end-organ failure, refractory congestion, inability to perform cardiopulmonary exercise test or peak oxygen consumption <12–14 mL/kg/min or <50% of expected value (see Table 16).
Current 2-year survival rates in patients receiving the latest LVAD types are comparable to those after heart transplantation. Among patients with fully magnetically levitated continuous-flow LVADs, 2-year and 5-year survival rates were 79% and 58.4%, respectively, in the MOMENTUM 3 trial with a previous LVAD type as the control group.604,605 These rates are considerably higher than could be expected from medical treatment in this population with >85% of patients in INTERMACS 1–3 at the time of LVAD implantation.604,605 Comparable outcomes were described in European and North American real-world populations.606–608
Adverse events may negatively affect QoL in patients receiving LVAD. Although pump thrombosis has become extremely rare, driveline infections remain similar to that with older devices.609 Right HF and arrhythmias may cause readmissions. Bleeding events can be minimized by avoiding antiplatelet therapy in addition to anticoagulation.610 A guidance document is available to support non-LVAD specialist healthcare providers outside of the implanting centre.609 Although now dated, the REMATCH trial is the only RCT comparing an LVAD as destination therapy with optimal medical
Figure 18 Treatment for advanced heart failure. ARVC, arrhythmogenic right ventricular cardiomyopathy; BTC, bridge to candidacy;
Page 57 · PDF
to study strategies of early LVAD implantation vs prolonged medical treatment: Early-VAD (NCT02387112),614 SweVAD,615 AMBU-VAD (NCT04768322), and TEAM-HF (NCT06526195). Histological examination of heart tissue after LVAD implantation or transplantation can identify potentially treatable or genetic causes of HF and is valuable for family screening and determining potential for myocardial recovery in LVAD patients.616–619
Table 16 Indications and contraindications for implantation of a left ventricular assist device Indicationsa HF with severely reduced LVEF and one of the following: • INTERMACS 1–2 with neurological and other end-organ recovery but no cardiac recovery on temporary MCS OR
Recommendation Table 13 — Recommendations for durable mechanical circulatory support in advanced heart failure (see Evidence Table 74)
OR • Severe symptoms and signs (NYHA class III/IV; INTERMACS >4) despite optimal FMT and GDIT, and at least one of the following: ⚬ Unable to exercise due to HF or, if able to perform CPET, with
pVO2 <12–14 mL/kg/min and/or <50% predicted value.
Durable MCS (LVAD) is recommended in
⚬ End-organ dysfunction (worsening kidney and/or hepatic function, group 2 pulmonary hypertension, cardiac cachexia)
selectedc patients with advanced HFrEF, despite FMT and GDIT, as BTT, BTC, BTR, or as destination therapy to improve symptoms and
due to reduced perfusion as indicated by cardiac index ≤2 L/ 2
min/m despite euvolaemic or therapy-resistant hypervolaemic status.
reduce the risk of death.604,611,613,620,621 Histopathological examination of explanted
⚬ Repeated HFH within the previous 12 months without an
surgery should be considered in patients with non-ischaemic HF to identify an aetiological
Contraindications Absolute:
diagnosis that may be treatable or facilitate
• Severe right ventricular dysfunction despite euvolaemic status • Severe irreversible end-organ (kidney and/or liver) disease
family screening.616,618 BTC, bridge to candidacy; BTR, bridge to recovery; BTT, bridge to transplantation; FMT, foundational medical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; LVAD, left ventricular assist device; MCS, mechanical circulatory support. a Class of recommendation. b Level of evidence. c Eligibility criteria are reported in Table 16.
• Severe irreversible neurological disease • Severe pulmonary disease • Contraindication to long-term oral anticoagulation • Medical non-adherence and/or other psychosocial limitations • Insufficient social supports to achieve compliant care in the outpatient setting • Psychological instability that jeopardizes proper follow-up and intensive therapeutic regime after implantation
8.2.3. Heart transplantation
Relative: • Obesity or malnutrition • Musculoskeletal disease that impairs rehabilitation • Malignancy (depending on type and prognosis) • Systemic infection • Alcohol or substance abuse within the past 6 months, or active smoking • Impaired cognitive function • Frailty CPET, cardiopulmonary exercise testing; HF, heart failure; HFH, heart failure hospitalization; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; NYHA, New York Heart Association; pVO2, peak oxygen consumption; RHC, right heart catheterization. a Indication by transplantation centre includes assessment of HF severity by RHC and/or CPET.
therapy in patients with advanced HF. REMATCH showed lower all-cause death with a previous type of LVAD therapy (HeartMate XVE) compared with medical treatment. However, mortality rates at 2 years were high in both arms.611 Other studies have not been randomized or compared different devices or post-implant strategies.604,606,607,610,612,613 Prospective RCTs have been initiated
• Severe peripheral arterial disease
Heart transplantation, although never evaluated in RCTs, remains the gold-standard treatment for advanced HF in the absence of contraindications. Post-transplant 1-year survival is 80%–90% and median survival is around 12.5 years.622,623 Transplantation significantly improves QoL and functional status. The main challenge after heart transplantation is the balance between efficacy and side effects of immunosuppression. Organ donor shortage remains the main limitation. Several countries have now started donation after circulatory death programmes, besides donation after brain death, with comparable mid-term results624,625 and, as a result, the numbers of heart transplantations have increased. Nevertheless, careful recipient selection remains essential, based on pre-transplant and post-transplant life expectancy (both influenced by pre-operative status and comorbidities). The main indications and contraindications for heart transplantation are listed in Table 17.580 Although patients younger than 65 years of age might be more appropriate candidates due to their overall life expectancy, most programmes accept patients up to 70 years of age, and biological age as well as chronological age must be taken into account. Surgical complexity [previous sternotomies, mediastinal radiation, adult congenital heart disease (ACHD)] should also be considered. The decision pathway to transplantation or LVAD is rarely straightforward and is unique to each patient.
heart tissue from LVAD or heart transplantation
obvious precipitating cause.
Page 58 · PDF
8.2.4. Symptom control and end-of-life care
Table 17 Indications and contraindications for heart transplantation
Advanced HF and no other therapeutic option (except for durable MCS as BTT) Absolute contraindications Inability to comply with the therapeutic regimen (e.g. dementia) Serious comorbidities with poor prognosis, not reversible with heart transplantation Other contraindications Active infectionb Severe peripheral arterial or cerebrovascular disease Elevated pulmonary vascular resistance (if pharmacologically irreversible)c Cancerd Irreversible liver dysfunction (cirrhosis) or irreversible kidney dysfunctione Systemic disease with multiorgan involvement BMI >35 kg/m2 or severe cachexia
Alcohol or substance abuse or active smoking within the past 6 months Psychological instability Insufficient social support to achieve compliant care in the outpatient setting
Eligibility for each option may change according to the specific conditions of each patient, which may also change over time. Some younger patients prefer to remain on LVAD for a prolonged period, rather than proceeding to transplantation immediately, to increase the potential number of life years gained. Other factors not related to the patient, such as average time on the heart transplantation waiting list, the centre’s surgical experience, and resources, can also influence decision-making.
Precipitating factors for AF – e.g. hyperthyroidism, toxic agents (e.g. including alcohol), valvular heart diseases, infection, diabetes, uncontrolled hypertension, obesity, sleep disorders, and volume overload – should be routinely identified and appropriately managed. Diuretic therapy is indicated to relieve congestion and may increase the chances of restoring sinus rhythm by reducing filling pressures and ventricular rate.
to FMT and GDIT, and without contraindications, to improve QoL and 622,626
FMT, foundational medical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure; QoL, quality of life. a Class of recommendation. b Level of evidence. c Eligibility criteria are reported in Table 17.
Heart transplantation is recommended in selectedc patients with advanced HF refractory
9.1.1. Atrial fibrillation
9.1.1.1. Identification of triggers and risk factor management
Recommendation Table 14 — Recommendations for heart transplantation (see Evidence Tables 75 and 76) Classa
9.1. Arrhythmias and conduction disturbances Heart failure and AF frequently coexist, with AF occurring in more than half of patients with HF, and HF occurring in more than one-third of patients with AF. The prevalence of AF is slightly higher in patients with HFpEF compared with HFrEF.195,628–631 The two conditions are deeply interrelated with shared risk factors and pathophysiological mechanisms. The coexistence of HF and AF is associated with a high risk of death, HFH, and stroke regardless of LVEF.195,628–631 HF induced by AF appears to have a more favourable outcome than HF causing AF.13,632 The management of patients with HF and AF include identification of triggers, prevention of embolic events, management of HF, and rate or rhythm control of AF.
BMI, body mass index; BTT, bridge to transplantation; CPET, cardiopulmonary exercise testing; HF, heart failure; LVAD, left ventricular assist device; MCS, mechanical circulatory support; RHC, right heart catheterization. a Indication by heart transplantation centre includes assessment of HF severity by RHC and/or CPET. b Active infection is a relative contraindication to transplantation, but infected LVAD may be an indication. c LVAD as bridge to candidacy should be considered. d Highly selected cases may be eligible, to be discussed with an oncologist. e Combined heart–liver or heart–kidney transplantation may be considered.
9. Cardiovascular comorbidities
9.1.1.2. Prevention of embolic events Oral anticoagulation is recommended in patients with HF and AF to reduce the risk of thromboembolism, according to the CHA2DS2-VA score (Table 18).118,633–635 However, patients with HCM and CA are at higher risk of thromboembolism irrespective of CHA2DS2-VA score, and anticoagulation is recommended for all these patients with AF.636–642 In the absence of mechanical prosthetic heart valves and/or moderate
Advance care planning is recommended in parallel to advanced HF treatments to determine goals of care and improve QoL along the disease trajectory.627 For indications and the core components of end-of-life care, see Supplementary data online, Table S20. End-of-life care in advanced HF focuses on symptom management (including breathlessness, pain, and anxiety and depression), patient comfort, and maintaining QoL ensuring personalized, compassionate care. It involves clear communication, shared decisionmaking, and integrating palliative or hospice care to support both the patient and their family. For further details on symptom management, see Supplementary data online, Section S5.2.3. Patients on durable MCS may request withdrawal of lifesustaining treatments because these are no longer consistent with their goals of care, because of poor QoL or newly developed serious comorbidities such as cancer. The MCS may be deactivated after careful evaluation of the patient’s wish and by, or under the supervision of, a specialized team. This decision has to take national laws into account. For details regarding follow-up in patients with advanced HF see section 11.6.2 and Recommendation Table 26.